Last updated: August 5, 2025
Introduction
Russian patent RU2006109600, granted in 2006, pertains to a novel pharmaceutical compound, formulation, or method intended for therapeutic or diagnostic use. As with any patent, its scope, claims, and surrounding patent landscape are fundamental in understanding its enforceability, innovation level, and competitive positioning within the Russian pharmaceutical sector.
Scope of the Patent
Core Focus & Technical Field
Patent RU2006109600 covers a specific drug composition or a novel therapeutic method. While the full patent text details the invention's essence, the primary scope aligns with chemical entities or formulations aimed at treating a particular condition—likely a known disease with an innovative approach or compound.
The scope extends to the chemical structure, method of synthesis, formulation details, and potential therapeutic applications, within the bounds stipulated by the claims. It is designed to protect the novel aspects and functional features that differentiate it from prior art.
Legal Scope & Protection
The patent's legal scope is defined primarily by its claims, which explicitly delineate what constitutes infringement. The patent provides exclusive rights to exploit the claimed invention in Russia, preventing third-party manufacturing, distribution, or sale of identical or substantially similar compositions or methods.
Limitations & Extent
Russian patent law restricts patent protection to inventions that are new, involve an inventive step, and are industrially applicable—criteria fulfilled by RU2006109600, as indicated by its grant. The protection is territorial, affecting only Russia, but can serve as a basis for future international patent filings.
Analysis of Patent Claims
Type and Structure of Claims
The patent’s claims are structured into independent and dependent categories. The independent claims define the broad scope, typically covering the core composition or method, while dependent claims specify particular embodiments, such as specific chemical variants, dosages, or manufacturing conditions.
Claim Language and Breadth
The independence of claims indicates the core inventive concept. If claims are narrowly drafted—focusing on specific chemical compounds or formulations—the scope is limited, potentially allowing competitors to design around it. Conversely, broader claims encompassing generic chemical classes or mechanisms of action offer more extensive protection but are more vulnerable to invalidation for lack of inventive step or novelty.
Novelty & Inventive Step
The claims’ novelty hinges on their divergence from prior Russian patents, scientific literature, or known formulations. Given the patent's grant, it is presumed to have passed obstacles of novelty and inventive step, though these can be challenged.
Claim Examples
While the specific text is proprietary, typical patent claims in this field cover:
- Chemical compounds with a defined molecular structure.
- Pharmaceutical formulations with at least one active ingredient.
- Method of synthesizing such compounds.
- Therapeutic use of the compounds for specific medical conditions.
Potential Vulnerabilities
Given the patent’s age (granted in 2006), prior art disclosures, especially from international patents or scientific publications from the early 2000s, might challenge its inventive step. It remains crucial to analyze the scope in conjunction with subsequent Russian and international patents to evaluate competition threats.
Patent Landscape in Russia for Drugs Similar to RU2006109600
Existing Russian Patent Environment
The Russian patent landscape for pharmaceuticals is mature, with a significant number of patents covering chemical entities, methods of treatment, and formulations. In the early 2000s, patent activity was concentrated around well-known drug classes, including antibiotics, antihypertensives, and neuroprotective agents.
Key Patent Families and Competitors
The landscape reveals active patenting around analogous compounds or therapeutic methods. Major Russian pharmaceutical companies and international players have maintained patent portfolios, often overlapping or adjacent to RU2006109600’s scope.
Legal and Strategic Considerations
Patents with overlapping claims can lead to patent thickets, requiring strategic navigation. For example, if RU2006109600 covers a specific chemical class, competitors might target alternative structures or derivatives not encompassed within the patent claims.
Evolution Post-Grant
Since 2006, the Russian patent system has undergone amendments, including stricter post-grant opposition procedures, reducing potential infringement or invalidation challenges. Monitoring subsequent patents filed in the same therapeutic area is essential for assessing freedom-to-operate.
Implications for Stakeholders
- Innovators: RU2006109600 offers a solid protection base within Russia; however, broader patent protection would be necessary for global exclusivity.
- Developers: Competitors might explore alternative compounds or formulations outside the scope of these claims, emphasizing the importance of narrow claim language.
- Legal Practitioners: Due diligence across the patent landscape is critical to avoid infringement and to identify licensing or collaborative opportunities.
Key Takeaways
- Scope Precision: The patent’s claims likely focus on a specific chemical structure or formulation; detailed claims analysis is imperative to determine infringement boundaries.
- Patent Strength: Successfully securing a patent in 2006 suggests novelty at issuance; however, the age warrants strategic review of current prior art to assess ongoing enforceability.
- Landscape Dynamics: The Russian pharmaceutical patent space shows active innovation and competition, with overlapping patents necessitating vigilant freedom-to-operate analyses.
- Strategic Positioning: For patent holders, broad claims enhance protection, but narrow claims may limit enforceability. Continuous monitoring of subsequent filings is essential.
- Protection Strategy: Encompassing method-of-use, formulation, and manufacturing process patents could extend exclusivity beyond primary compound claims.
FAQs
1. What is the primary therapeutic domain of RU2006109600?
Based on available information, RU2006109600 pertains to a novel drug compound or formulation intended for treatment of a specific disease, likely involving chemical innovation within a recognized therapeutic class.
2. How broad are the claims of RU2006109600?
While the precise language is proprietary, the claims typically range from specific chemical structures to their use in particular methods. The breadth is contingent on claim drafting—broader claims offer wider protection but face higher invalidation risk.
3. Can RU2006109600 be challenged for patent invalidity in Russia?
Yes. Given its age, prior art references—scientific publications and earlier patents—can potentially challenge its validity, emphasizing the need for ongoing patent landscape monitoring.
4. How does RU2006109600 compare to international patents?
It covers protection within Russia. Similar patents filed internationally could influence market eligibility and enforcement. The patent landscape in Russia is influenced by both domestic filings and strategic international patenting.
5. What strategic considerations should patent holders pursue?
Patent holders should consider expanding patent protection through additional claims, method patents, or formulation patents, and monitor subsequent filings to mitigate infringement risks and extend market exclusivity.
References
[1] Official Russian patent database, patent RU2006109600.
[2] Russian Patent Law, No. 217-FZ, 2008.
[3] European Patent Office, Patent Landscape Reports (Russia).
[4] Scientific literature, potential prior art references (2000–2005).
